Ursolisin

Active substance

Ursodeoxycholic acid

Strenght and pharmaceutical forms

​150 mg hard capsules – 20 hard capsules
150 mg hard capsules – 30 hard capsules
150 mg hard capsules – 40 hard capsules
300 mg hard capsules – 10 hard capsules
300 mg hard capsules – 20 hard capsules

ATC

A05AA02 - Hepatobiliary antilithogen, litolithic

Therapeutic Indications

Qualitative and quantitative alterations of biligenetic function, including bile-overexpressing cholesterol forms, to oppose the formation of cholesterol calculations or to achieve conditions for dissolution if radiolucent calculations already exist: in particular, gallbladder stones in functional gallbladder and calculations in residual choledocus or recurrent ones after surgery on the bile ducts; Biliary dyspepsia.

Marketing Authorization Holder

Aesculapius Farmaceutici S.r.l.

Download area

Summary of Product Characteristics - Ursolisin

Clinical Review from British Journal of Medicine & Medical Research